Drug Trial Radar · NCT04792034
Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 6, 2025
Primary completion
Dec 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- LXO IrelandIndustry
- Sponsor type
- Industry
- Collaborators
- Omnivium Pharmaceuticals LLC
- First posted
- Mar 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetic (PK) properties, safety and tolerability following a single dose administration of GOPRELTO® or NUMBRINO™ as an anesthetic for diagnostic procedures and surgeries on or through the mucous membranes of the nasal cavities in pediatric adolescent subjects.
Conditions
- ENT Disorder
- Nasal Procedures
- Nasal Anesthesia
- Nasal Mucosa Surgery
Interventions
Cocaine Hydrochloride Nasal SolutionDrug
Topical Anesthetic
Cocaine Hydrochloride Nasal SolutionDrug
Topical Anesthetic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Blood pressureTime frame: Baseline and every 5 minutes through 90 minutes post-pledget application.
- Changes in Heart rateTime frame: Baseline and every 5 minutes through 90 minutes post-pledget application.
- Changes in Respiratory RateTime frame: Baseline and every 5 minutes through 90 minutes post-pledget application.
- Physical examinationTime frame: Screening Visit
- ElectrocardiogramTime frame: Screening Visit, and on Day 1 at Baseline (pre-dose), continuously during treatment, and through 90 minutes post-pledget application
- Pulse OximetryTime frame: Screening Visit, and on Day 1 at Baseline (pre-dose), every 5 minutes during treatment, and through 90 minutes post-pledget application
- Incidence of Adverse events (AEs)Time frame: From Day 1 (pledget application) through the final follow-up call at Day 10.
- Maximum observed plasma concentration (Cmax)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
- Time to maximum observed plasma concentration (Tmax)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
- Area under the plasma concentration versus time curve from time of dosing (0) to the time of last quantifiable concentration (AUClast)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
- Area under the plasma concentration versus time curve from time of dosing (0) to infinity (AUCinf)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
- Terminal rate constant in plasma from the negative of the regression line slope through the ln-plasma concentration versus time data defining the terminal phase [kel (λz)]Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
- Terminal half-life in plasma calculated from the kel as ln(2)/kel (t½)Time frame: Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
SCENT Ambulatory Surgical Center, 145 Park Central Dr, Suite 200
Columbia, South Carolina · Recruiting
SCENT Sleep and Allergy, 110 Highland Center Drive
Columbia, South Carolina · Completed
SCENT Sleep and Allergy, 145 Park Central
Columbia, South Carolina · Completed
South Carolina ENT, Sleep and Allergy
Columbia, South Carolina · Completed
SCENT Sleep and Allergy, 15 Exchange Dr.
Lugoff, South Carolina · Completed
Carolina Pines Ear Nose Throat & Allergy Associates LLC, 2562 Kinard Street
Newberry, South Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.